118 related articles for article (PubMed ID: 37796543)
1. Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer.
Zhao C; Zhang Y; Zhang J; Li S; Liu M; Geng Y; Liu F; Chai Q; Meng H; Li M; Li J; Zheng Y; Zhang Y
J Med Chem; 2023 Oct; 66(20):14150-14174. PubMed ID: 37796543
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Novel Pyrrolo[2,3-
Liang X; Tang S; Liu X; Liu Y; Xu Q; Wang X; Saidahmatov A; Li C; Wang J; Zhou Y; Zhang Y; Geng M; Huang M; Liu H
J Med Chem; 2022 Jan; 65(2):1243-1264. PubMed ID: 33586434
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
Jiang XC; Tu FH; Wei LY; Wang BZ; Yuan H; Yuan JM; Rao Y; Huang SL; Li QJ; Ou TM; Wang HG; Tan JH; Chen SB; Huang ZS
J Med Chem; 2022 Sep; 65(18):12346-12366. PubMed ID: 36053318
[TBL] [Abstract][Full Text] [Related]
4. Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
Wu B; Fathi S; Mortley S; Mohiuddin M; Jang YC; Oyelere AK
Bioorg Med Chem; 2020 Mar; 28(6):115345. PubMed ID: 32061484
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Thieno[2,3-
Pan Z; Li X; Wang Y; Jiang Q; Jiang L; Zhang M; Zhang N; Wu F; Liu B; He G
J Med Chem; 2020 Apr; 63(7):3678-3700. PubMed ID: 32153186
[TBL] [Abstract][Full Text] [Related]
7. Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer.
Zeng H; Qu J; Jin N; Xu J; Lin C; Chen Y; Yang X; He X; Tang S; Lan X; Yang X; Chen Z; Huang M; Ding J; Geng M
Cancer Cell; 2016 Sep; 30(3):459-473. PubMed ID: 27622335
[TBL] [Abstract][Full Text] [Related]
8. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
[TBL] [Abstract][Full Text] [Related]
9. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of dual BRD4/Src inhibitors for treatment of triple-negative breast cancer.
Wang Y; Huang A; Chen L; Sun F; Zhao M; Zhang M; Xie Y; Xu S; Li M; Hong L; Li G; Wang R
Eur J Med Chem; 2024 Jan; 264():116009. PubMed ID: 38070430
[TBL] [Abstract][Full Text] [Related]
11. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
Wawruszak A; Luszczki JJ; Kalafut J; Okla K; Halasa M; Rivero-Muller A; Stepulak A
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357442
[TBL] [Abstract][Full Text] [Related]
12. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.
Rhodes LV; Tate CR; Segar HC; Burks HE; Phamduy TB; Hoang V; Elliott S; Gilliam D; Pounder FN; Anbalagan M; Chrisey DB; Rowan BG; Burow ME; Collins-Burow BM
Breast Cancer Res Treat; 2014 Jun; 145(3):593-604. PubMed ID: 24810497
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy.
Zhang J; Tang P; Zou L; Zhang J; Chen J; Yang C; He G; Liu B; Liu J; Chiang CM; Wang G; Ye T; Ouyang L
J Med Chem; 2021 Dec; 64(24):18025-18053. PubMed ID: 34908415
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel PAK1/HDAC6 dual inhibitor ZMF-23 that triggers tubulin-stathmin regulated cell death in triple negative breast cancer.
Zhang J; Chen X; Chen G; Wang H; Jia L; Hao Y; Yao D
Int J Biol Macromol; 2023 Nov; 251():126348. PubMed ID: 37586623
[TBL] [Abstract][Full Text] [Related]
15. Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells.
Yang F; Wang F; Liu Y; Wang S; Li X; Huang Y; Xia Y; Cao C
Life Sci; 2018 Nov; 213():149-157. PubMed ID: 30352240
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and Anti-Triple Negative Metastatic Breast Tumor Cell Properties of Psammaplins.
Zhou YD; Li J; Du L; Mahdi F; Le TP; Chen WL; Swanson SM; Watabe K; Nagle DG
Mar Drugs; 2018 Nov; 16(11):. PubMed ID: 30423844
[TBL] [Abstract][Full Text] [Related]
17. WMJ-8-B, a novel hydroxamate derivative, induces MDA-MB-231 breast cancer cell death via the SHP-1-STAT3-survivin cascade.
Chuang YF; Huang SW; Hsu YF; Yu MC; Ou G; Huang WJ; Hsu MJ
Br J Pharmacol; 2017 Sep; 174(17):2941-2961. PubMed ID: 28646512
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
Shieh JM; Wei TT; Tang YA; Huang SM; Wen WL; Chen MY; Cheng HC; Salunke SB; Chen CS; Lin P; Chen CT; Wang YC
PLoS One; 2012; 7(1):e30240. PubMed ID: 22279574
[TBL] [Abstract][Full Text] [Related]
19. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
20. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y
Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]